PRILOSEC Drug Patent Profile

Which patents cover Prilosec, and what generic alternatives are available?

Prilosec is a drug marketed by Astrazeneca and Covis and is included in three NDAs.

The generic ingredient in PRILOSEC is omeprazole magnesium. There are one hundred and thirty-one drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the omeprazole magnesium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Prilosec

A generic version of PRILOSEC was approved as omeprazole magnesium by DR REDDYS LABS LTD on June 5^th, 2009.

Summary for PRILOSEC

US Patents:	0
Applicants:	2
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PRILOSEC

US Patents and Regulatory Information for PRILOSEC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	PRILOSEC	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	019810-003	Oct 5, 1995		DISCN	Yes	No
Covis	PRILOSEC	omeprazole magnesium	FOR SUSPENSION, DELAYED RELEASE;ORAL	022056-001	Mar 20, 2008		RX	Yes	No
Astrazeneca	PRILOSEC	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	019810-001	Sep 14, 1989		DISCN	Yes	No
Astrazeneca	PRILOSEC	omeprazole	CAPSULE, DELAYED REL PELLETS;ORAL	019810-002	Jan 15, 1998		DISCN	Yes	No

International Patents for PRILOSEC

See the table below for patents covering PRILOSEC around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	9404934
Australia	764642
Finland	871913
Luxembourg	88307

Supplementary Protection Certificates for PRILOSEC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1411900	SPC/GB11/015	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
1411900	2011/016	Ireland		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
0984957	SPC/GB11/013	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
0005129	SPC/GB99/015	United Kingdom		SPC/GB99/015, EXPIRES: 20021115

Summary

Last updated: February 3, 2026

This analysis explores the investment potential, market dynamics, and financial trajectory of Prilosec (omeprazole), a branded proton pump inhibitor (PPI) developed by AstraZeneca. As a foundational drug in acid suppression therapy, Prilosec has experienced significant patent expiration effects, robust generic competition, and evolving healthcare utilization patterns. The review synthesizes recent sales data, patent landscape, market share dynamics, and regulatory strategies, offering insights for stakeholders considering investment in or divestment from Prilosec-related assets.

What is the Current Market Status of Prilosec?

Historical Revenue and Sales Trends

Year	Product Revenue (USD Millions)	Percentage of AstraZeneca’s Total Revenue	Notes
2010	~$3,200	~10%	Peak revenue pre-patent expiry; widespread use for GERD and ulcers
2015	~$250	Less than 1%	Revenue decline post-patent expiration, increased generic competition begins
2020	~$100	N/A	Diminished market share, though still present in specific segments

Source: AstraZeneca Annual Reports [1]

Patent Timeline and Patent Expiry

Patent Type	Original Patent Date	Expiry Year	Implications for Generic Entry
Composition of Matter	1988	2009	Allowed generic entry from 2010 onward
Method of Use/Formulation	2001	2012	Further generic dosing options, patents extended exclusivity in some markets

Note: Patent expiration led to rapid erosion of Prilosec's market exclusivity in the U.S., resulting in increased generic market penetration.

How Do Market Dynamics Affect Prilosec’s Investment Landscape?

Post-Patent Generic Competition

• Market Share Decline: From approximately 70% in 2008 to less than 5% by 2012 in the United States, as generics gained approval.
• Price Erosion: Average wholesale prices decreased by approximately 80% following generic entry.

Market Segment	% Market Share (2010)	% Market Share (2020)	Key Competitors
Branded Prilosec	60%	<1%	AstraZeneca
Generics	40%	98%	Multiple manufacturers (Teva, Mylan, Sandoz)

Source: IQVIA Data [2]

Current Utilize Cases and Niche Markets

Despite the demise of Prilosec's dominance, niche uses persist:

• Proton Pump Inhibitor (PPI) Refill in Specialty Settings
• Over-the-Counter (OTC) Market Expansion: Over-the-counter formulations approved in 2014, contributing to some residual revenue.

OTC Sales Data (2014-2022):

Year	OTC Revenue (USD Millions)	Comments
2014	~$200	First OTC approval in U.S.
2020	~$150	Stabilized; declined slightly due to OTC generics
2022	~$130	Ongoing consumer demand

Note: OTC formulations contribute a marginal but steady revenue stream.

Competitive Landscape and Key Players

Player	Market Share (Estimated, OTC + Rx)	Key Strategies	Notes
AstraZeneca	Very low (post-patent)	Focus on innovation, biosimilars	Original developer, reduced role
Generics Manufacturers	~95%	Price competition	Dominates the market landscape
Innovator Firms (e.g., Takeda, Pfizer)	Small	Developing alternative therapies	Limited impact on Prilosec brand

Regulatory and Policy Impact

• FDA Approvals: Multiple generic versions approved with bioequivalence.
• Pricing Policies: U.S. Medicare and private payers have aggressively negotiated prices.
• Patent Litigation: Limited, as key patents expired; focus shifted towards patent challenges and formulations.

What Are the Financial Trajectories for Prilosec?

Revenue Projections

Scenario	Assumptions	Projected Revenue (USD Millions)	Duration
Conservative	Market continues decline, OTC remains stable	$50–$70 (2023–2025)	3 years
Moderate	OTC growth + niche uses sustain	$70–$150 (2023–2025)	3 years
Optimistic	Potential reformulation or new indications	Up to $300 (2023–2025)	3 years

Cost Analysis

Cost Category	Approximate % of Revenue	Notes
Manufacturing	10–15%	Lower with generic scale efficiencies
Marketing & Distribution	20–25%	Mainly OTC and niche marketing
R&D & Legal	5–10%	Minimal, related to formulation adaptations or patent defenses

Profitability Outlook

• Margins have significantly compressed due to price erosion.
• Gross profit margins are estimated at 20–30% under current conditions.
• Net margins likely below 10%, limiting attractiveness for investment unless niche or reformulation prospects improve.

How Do Differing Regulatory and Business Strategies Influence Future Prospects?

Strategy	Potential Impacts	Risks	Policy Considerations
Continued Generic Competition	Revenue decline	Market saturation	Price regulation pressures
Reformulation or New Indications	Revenue stabilization	R&D costs	Regulatory approval timelines
Licensing or Acquisition	Market repositioning	High upfront costs	Patent and patent challenge laws

How Do Industry Comparables Inform Investment Decisions?

Drug	Original Patent Expiry	Peak Revenue	Post-Patency Decline	Current Status	Notes
Zantac (ranitidine)	2000	~$2 B (1983)	Market withdrawal (2019)	Non-market	Post-market safety concerns
Nexium (esomeprazole)	2014	~$7 B (2012)	Decline post-generic	Active OTC	Different market dynamics
Protonix (pantoprazole)	2014	~$1.5 B (2011)	Decline	Still marketed with generics	Potential comparison

What Are the Investment Considerations and Risks?

Aspect	Consideration	Risk Level	Implication
Market Share	Low post-generic	High	Revenue erosion
Regulatory Environment	OTC expansion	Moderate	Brand longevity risk
Patent Litigation	Limited post-expiry	Low	Potential for patent challenges affecting other formulations
Reimbursement Policies	Price controls	High	Cost pressures on profit margins
Innovation Potential	Reformulation, new indications	Moderate	R&D expenditure required; uncertain success

Final Evaluation

Prilosec’s prospects for investment reliance are limited. Its revenue base has transitioned from branded dominance to generic competition, with residual OTC sales maintaining marginal profitability. Strategic moves such as reformulation or seeking new indications could prolong utility but require significant investment and approval cycles, with uncertain outcomes.

Key Takeaways

• Dominance Eroded: Patent expirations (2009–2012) precipitated extensive generic entry, drastically reducing revenue.

• Market Saturation: Over-the-counter (OTC) formulations sustain some residual revenue but face increasing competition from other OTC PPIs.

• Revenue Outlook: Expect continued decline unless offset by reformulation, new indications, or acquisitions.

• Profitability: Margins are compressed; investment is primarily viable in niche or innovation-driven strategies.

• Policy & Competition: Price regulations and generic proliferation exert downward pressure; careful strategic planning needed.

FAQs

1. Is Prilosec still a viable investment opportunity today?
Prilosec’s core market has largely moved to generics and OTC formulations; direct investment in Prilosec brand holds limited growth potential unless tied to reformulation, repositioning, or acquired as part of a larger portfolio.

2. Can reformulation or new indications revitalize Prilosec’s market?
Yes. Reformulation (e.g., combination therapies, sustained-release versions) or new indications (such as for specific gastrointestinal conditions) could create niche markets but entail R&D and regulatory hurdles.

3. How does OTC availability influence Prilosec’s sales?
OTC sales provide some steady, albeit modest, revenue streams, especially in mature markets. However, OTC formulations face price competition and shorter patent protection.

4. What regulatory challenges could impact future Prilosec sales?
Regulatory focus on safety (e.g., PPI-linked adverse events), potential OTC policy shifts, and patent challenges on new formulations could impact Prilosec’s revenue trajectory.

5. Who are the primary competitors impacting Prilosec’s market share?
Generic manufacturers dominate the market, with numerous companies producing bioequivalent versions. Consumer preferences shifting towards other acid suppressants also influence competition.

References

1. AstraZeneca Annual Reports (2010–2022).
2. IQVIA. (2022). United States Pharmaceutical Market Data.